Literature DB >> 19682062

A 12-month longitudinal study of calcium metabolism and bone turnover during valproate monotherapy.

A Verrotti1, S Agostinelli, G Coppola, P Parisi, F Chiarelli.   

Abstract

BACKGROUND AND
PURPOSE: Treatment with valproate (VPA) can cause changes in bone mineral metabolism, but the real influences and the underlying pathologic mechanisms are still unclear and under discussion. The aim of this study was to examine the changes on calcium metabolism and bone turnover in post-pubertal male patients with newly diagnosed idiopathic generalized epilepsy (IGE) before (baseline evaluation) and 12 months after VPA monotherapy (second evaluation).
METHODS: Participants included 20 post-pubertal males with IGE, aged 16.5-22.1 years. Also 20 post-pubertal sex- and age-matched healthy controls were evaluated. Physical activity, calcium and vitamin D intake were determined. Laboratory samples were obtained to measure biochemical parameters of bone metabolism and bone turnover: serum calcium, phosphate, magnesium, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, intact parathyroid hormone, total alkaline phosphatase, bone alkaline phosphatase (bone-ALP), osteocalcin (OC), carboxy-terminal propeptide of type I procollagen (PICP) and carboxy-terminal telopeptide of type I collagen (ICTP).
RESULTS: At baseline evaluation, there were no significant differences between controls and patients parameters. At second evaluation, patients showed both markers of bone formation and resorption significantly higher than baseline values (bone-ALP: 51.2 +/- 9.9 vs. 57.3 +/- 9.3 U/l, P < 0.01; OC: 8.1 +/- 1.1 vs. 10.4 +/- 1.5 microg/l, P < 0.01; PICP: 138.7 +/- 16.4 vs. 152.6 +/- 17.1 microg/l, P < 0.01; ICTP: 3.8 +/- 0.8 vs. 5.9 +/- 0.6 microg/l, P < 0.01).
CONCLUSIONS: Valproate monotherapy in epileptic post-pubertal males causes a significant increase of bone turnover.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19682062     DOI: 10.1111/j.1468-1331.2009.02773.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  7 in total

1.  Treatment of epilepsy to optimize bone health.

Authors:  Alison M Pack
Journal:  Curr Treat Options Neurol       Date:  2011-08       Impact factor: 3.598

Review 2.  Dispensability of Annual Laboratory Follow-Up After More than 2 Years of Valproic Acid Use: A Systematic Review.

Authors:  Rosanne W Meijboom; Koen P Grootens
Journal:  CNS Drugs       Date:  2017-11       Impact factor: 5.749

Review 3.  Effects of antiepileptic drugs on bone health and growth potential in children with epilepsy.

Authors:  Peter Vestergaard
Journal:  Paediatr Drugs       Date:  2015-04       Impact factor: 3.022

4.  Bone turnover markers in epileptic patients under chronic valproate therapy.

Authors:  Mohammad Zare; Mohammad R A Ghazvini; Maseumeh Dashti; Mohammad R Najafi; Amir M Alavi-Naeini
Journal:  J Res Med Sci       Date:  2013-04       Impact factor: 1.852

5.  Bone status in patients with epilepsy: relationship to markers of bone remodeling.

Authors:  Sherifa A Hamed; Ehab M M Moussa; Ahmad H Youssef; Mohammed A Abd ElHameed; Eman NasrEldin
Journal:  Front Neurol       Date:  2014-08-04       Impact factor: 4.003

6.  Cerebral Palsy and Epilepsy in Children: Clinical Perspectives on a Common Comorbidity.

Authors:  Piero Pavone; Carmela Gulizia; Alice Le Pira; Filippo Greco; Pasquale Parisi; Giuseppe Di Cara; Raffaele Falsaperla; Riccardo Lubrano; Carmelo Minardi; Alberto Spalice; Martino Ruggieri
Journal:  Children (Basel)       Date:  2020-12-31

7.  Association between serum vitamin D status and the anti-seizure treatment in Chinese children with epilepsy.

Authors:  Na Dong; Hong-Li Guo; Ya-Hui Hu; Jiao Yang; Min Xu; Le Ding; Jin-Chun Qiu; Zhen-Zhou Jiang; Feng Chen; Xiao-Peng Lu; Xiao-Nan Li
Journal:  Front Nutr       Date:  2022-08-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.